Evaluation of coagulation with TEG in patients diagnosed COVID-19
Autor: | Ahmet Topal, Serkan Küççüktürk, Resul Yilmaz, Celalettin Vatansev, Mehmet Ali Karaselek, Şebnem Yosunkaya, Adem Küçük, Hülya Vatansev |
---|---|
Přispěvatelé: | Küççüktürk, Serkan |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
medicine.medical_treatment law.invention D-Dimer law Coagulopathy Internal medicine D-dimer Fibrinolysis Thromboelastography medicine Coagulation testing Outpatient clinic Humans Blood Coagulation medicine.diagnostic_test business.industry COVID-19 Thrombosis General Medicine medicine.disease Intensive care unit Thrombelastography Blood Coagulation Tests business |
Zdroj: | Turkish journal of medical sciences. 52(1) |
ISSN: | 1303-6165 |
Popis: | PubMed ID 34773688 WOS:000761923700004 Background and aim: A high D-dimer level may indicate the risk of coagulopathy and mortality in COVID-19 patients. Thromboelastography (TEG) is a test that evaluates clot formation and fibrinolysis in real-time, unlike routine coagulation tests. The study aimed to investigate the coagulation process with TEG in patients diagnosed with COVID-19. Materials and Methods: The study was performed at our university hospital, chest diseases outpatient clinic as a cross-section study. A total of 51 patients with 23 high D-dimer levels group (HDG) and 28 low D-dimers group (LDG) were included in the study. TEG analysis was performed at the pretreatment evaluation in these two groups. Results: D-dimer and fibrinogen levels of the HDG were higher than those of the LDG (550 vs. 90 ng/mL, p < 0.001; 521 vs. 269 mg/ dL, p < 0.001, respectively). In TEG analysis, HDG’s R and K values were lower than LDG, and HDG’s Angle, MA, and CI values were higher than LDG (p = 0.037; p < 0.001; p < 0.001; p < 0.001; p [removed]62°, MA was 60.4 mm. Conclusion: Our study showed that the risk of thrombosis might increase in COVID-19 patients who are not hospitalized in the intensive care unit. Thrombosis risk should be investigated with TEG analysis and laboratory tests in every patient diagnosed with COVID-19, and treatment should be started for risky patients. |
Databáze: | OpenAIRE |
Externí odkaz: |